1 |
Talmadge E. King, Jr. Interstitial Lung Diseases. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, eds. Harrison's Principles of Internal Medicine. 16th ed. New York, NY: McGraw-Hill; 2005.
|
2 |
Schwarz MI, King TE Jr. Approach to the evaluation and diagnosis of interstitial lung disease. In: King TE Jr, Schwarz MI eds. Interstitial lung disease. 4th ed. B.C.Becker, Hamilton, ON, Canada. 2003.
|
3 |
King TE Jr. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med 2005; 172(3): 268-79.
DOI
ScienceOn
|
4 |
Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9: 148-65.
|
5 |
Navon-Venezia SH, Ronen Ben-Ami R, Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 2005; 18: 306-13.
DOI
ScienceOn
|
6 |
Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008; 358(12): 1271-81.
DOI
ScienceOn
|
7 |
Kang SO, Rhee HJ, Lee SH. An Evalution of Antibiotic Use in the Hospitalized Burn patients, Kor J Clin Pharm 2002; 12(2): 55-64.
|
8 |
Kim JS, Oh JM. The Patterns of Infection and Therapy in Cancer Patients Receiving Chemotherapy. J Kor Soc Health-Syst Pharm 2000; 17(4): 481-500.
|
9 |
Herruzo R, de la Cruz J, Fernandez-Acenero MJ, et al., Two consecutive outbreaks of Acinetobacter baumannii 1-1 in a burn intensive care unit for adults. Burns 2004; 30(5): 419-23.
DOI
ScienceOn
|
10 |
Zarrilli R, Crispino M, Bagattini M, et al., Molecular epidemiology of sequential outbreaks of Acinetobacter baumannii in an intensive care unit shows the emergence of carbapenem resistance. J Clin Microbiol 2004; 42(3): 946-53.
DOI
ScienceOn
|
11 |
Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrugresistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med. Microbiol 2006; 55: 1619-29.
DOI
ScienceOn
|
12 |
Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 2004; 38(9): 1449-59.
DOI
ScienceOn
|
13 |
Michalopoulos A, Falagas ME. Treatment of Acinetobacter infections. Expert Opin Pharmacother 2010; 11(5): 779-88.
DOI
ScienceOn
|
14 |
Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54(2): 628-34.
DOI
ScienceOn
|
15 |
Nunley DR, Bauldoff GS, Mangino JE, Pope-Harman AL. Mortality associated with Acinetobacter baumannii infections experienced by lung transplant recipients. Lung 2010; 188(5): 381-5.
DOI
ScienceOn
|
16 |
Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43(Suppl 2): 49-56.
DOI
|
17 |
Lee K, Kim MN, Kim JS, Hong HL, Kang JO, Shin JH, Park YJ, Yong D, Jeong SH, Chong Y; The KONSAR Group. Further Increases in Carbapenem-, Amikacin-, and Fluoroquinolone-Resistant Isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR Study 2009. Yonsei Med J 2011; 52(5): 793-802.
DOI
ScienceOn
|
18 |
Neonakis IK, Spandidos DA, Petinaki E. Confronting multidrug-resistant Acinetobacter baumannii: a review. Int J Antimicrob Agents 2011; 37(2): 102-9.
DOI
ScienceOn
|
19 |
Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007; 27(8): 1198-201.
DOI
ScienceOn
|
20 |
Micromedex Healthcare Series Web site.
|
21 |
Michalopoulos A, Fotakis D, Virtzili S, et al., Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 2008; 102(3): 407-12
DOI
ScienceOn
|
22 |
Food and Drug Administration Web site: Colistimethate Information. Available at: http://www.fda.gov/Drugs/Drug Safety/Postmarket Drug Safety Information for Patientsand Providers/ucm118080.htm
|
23 |
Falagas ME, Rafailidis PI, Matthaiou DK, et al., Pandrugresistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 2008; 32(5): 450-4.
DOI
ScienceOn
|